

increasing the elimination of nasopharynx⁹ and to correct nephropathy.⁴

As a result, pertussis is a rare cause of secondary CNS, therefore edema or proteinuria, which can be detected in infants who are followed due to pertussis, should be stimulating for CNS.

Funding

The authors have no financial or competing interests in relation to this work.

Conflict of interest

The authors declare that there is no conflict of interest.

REFERENCES

1. Pais P, Avner E. Nephrotic syndrome. In: Kliegman RM, Stanton B, St Geme JW, editors. *Nelson textbook of pediatrics*. 20th ed. Philadelphia: Elsevier Company; 2016. p. 2521–8.
2. Long S. Pertussis (*Bordetella pertussis* and *Bordetella parapertussis*). In: Kliegman RM, Stanton B, St Geme JW, editors. *Nelson textbook of pediatrics*. 20th ed. Philadelphia: Elsevier Company; 2016. p. 1377–82.
3. Kim JJ, Clothier J, Sebire NJ, Milford DV, Moghal N, Trompeter RS. Nephrotic syndrome in infancy can spontaneously resolve. *Pediatr Nephrol* (Berlin, Germany). 2011;26:1897–901. <http://dx.doi.org/10.1007/s00467-011-1911-0>. PMID: 21611885 [Epub ahead of print].
4. Kaynak-Turkmen M, Cengiz-Erdem F, Sonmez F, Girisgen I, Telli M, Berdeli A. A newborn with pertussis accompanying

- nephrotic syndrome. *Turk J Pediatr*. 2014;56:665–8. PMID: 26388601 [Epub ahead of print].
5. Tryggvason K, Patrakka J, Wartiovaara J. Hereditary proteinuria syndromes and mechanisms of proteinuria. *N Engl J Med*. 2006;354:1387–401.
6. Koziell A, Grech V, Hussain S, Lee G, Lenkkeri U, Tryggvason K, et al. Genotype/phenotype correlations of NPHS1 and NPHS2 mutations in nephrotic syndrome advocate a functional inter-relationship in glomerular filtration. *Hum Mol Genet*. 2002;11:379–88.
7. Holmberg C, Jalanko H. Nephrotic syndrome in the first year of life. In: Kher KK, Greenbaum LA, Schnaper HW, editors. *Clinical pediatric nephrology*. 3rd ed. Florida: Taylor & Francis; 2017. p. 353–65.
8. Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. *Pediatr Infect Dis J*. 2005;24:S58–61.
9. Munoz FM, editor. *Pertussis in infants, children, and adolescents: diagnosis, treatment, and prevention*. *Seminars in pediatric infectious diseases*. Elsevier; 2006.

Mervan Bekdas^{a,*}, Recep Eroz^b, Busra Cihan^a

^a Department of Pediatrics, Abant Izzet Baysal University Medical Faculty, Bolu, Turkey

^b Department of Medical Genetics, Duzce University Medical Faculty, Duzce, Turkey

* Corresponding author.

E-mail address: merbek14@yahoo.com (M. Bekdas). <https://doi.org/10.1016/j.nefro.2019.03.009>

0211-6995/© 2019 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Renal damage secondary to checkpoint inhibitors[☆]

Fracaso renal agudo asociado a inhibidores check-point

Dear Editor,

The treatment of renal carcinoma (CR) has been revolutionised thanks to the use of antiproliferative and immunomodulatory drugs. Sunitinib (SUN) is a tyrosine kinase (TK) inhibitor with antiproliferative and anti-angiogenic effect.¹ Nivolumab (NIV) is a human monoclonal antibody, a checkpoint inhibitor, which prevents the cancer cells from evading the immune system, enhancing the patient's immune response.² Both drugs have been shown to increase RCC survival, but have also been

linked to toxicity in different organs. We describe here the case of a patient who developed renal damage associated with the use of SUN and NIV.

This was a 70-year-old male with a pacemaker due to Mobitz AV block, hypertension (HTN) and chronic kidney disease (baseline creatinine 1.4–1.5 mg/dl) due to loss of nephron mass after right nephrectomy due to RC (pT3b Nx Mx) in 2014.

After recurrence of the cancer, he received first-line treatment with SUN, which was discontinued because toxicity, including renal toxicity, leaving serum creatinine (sCr) levels of 1.4–1.8 mg/dl. Six months later, the cancer progressed,

DOI of original article: <https://doi.org/10.1016/j.nefro.2019.05.004>.

[☆] Please cite this article as: Moliz C, Cavero T, Morales E, Gutiérrez E, Alonso M, Praga M. Fracaso renal agudo asociado a inhibidores check-point. *Nefrologia*. 2020;40:206–208.




Fig. 1 – A) Glomerulus with reinforcement of the glomerular pattern, mesangial cell proliferation and thickening of the capillary walls. PAS, 40 × . **B)** Double contour images (marked with arrows). Silver technique. **C)** Moderate fibrosis, tubular atrophy and lymphoplasmacytic infiltrates in the interstitium. Masson, 40 × . **D)** Arterioles with smooth muscle hyperplasia and decreased lumen. Masson.

and it was decided to give a second-line treatment with NIV.

Eight weeks after the second dose of NIV, he was admitted to Medical Oncology with impaired renal function (sCr 2.8 mg/dl). Urine sediment showed albuminuria (100–200 mg/dl), leucocyturia and microhaematuria. On physical examination, the patient had crackles in lung bases and oedema to the middle third of both lower limbs. NIV was discontinued and he was started on diuretic treatment. At 48 h his renal function worsened (Cr_s 4.9 mg/dl), so the Nephrology Service was consulted.

After assessment by Nephrology, tests were completed with 24 h proteinuria (1.98 g/day). Obstructive uropathy was ruled out, as well as other systemic causes of acute kidney injury (AKI) (serology, autoimmunity, complement, immunoelectrophoresis, peripheral blood extension, all negative). It was decided to perform a renal biopsy to confirm possible drug-related AKI.

The renal biopsy (Fig. 1) confirmed the presence of interstitial lymphoplasmacytic infiltrate suggestive of acute interstitial nephritis (AIN) due to NIV. High-dose pulse steroid therapy was given over three days (250 mg on the first day and 125 mg on the second and third days), followed by oral (0.5 mg/kg) in tapering regimen, which recovered the patient's baseline Cr_s and reduced the proteinuria (0.8 g/day).

He received prophylaxis for *Pneumocystis jirovecii* with Septrin. In addition, examination of the histology sample revealed segmental thickening of capillary walls with images of double contours, compatible with membranoproliferative glomerulonephritis, as well as podocyte hypertrophy and chronic vascular damage with a decrease in vascular lumen of more than 75%, interstitial fibrosis and moderate tubular atrophy. Immunofluorescence showed no deposition of immunoglobulins or immune complexes, and electron microscopy (Fig. 2) confirmed enlargement of the lamina rara interna visible in thrombotic microangiopathy (TMA), for which these lesions were attributed to the previous treatment with SUN.

It is known that the administration of anti-angiogenic drugs, such as SUN, may cause HTN, proteinuria and TMA.^{1,3} There have even been cases recently reported of AIN in association with these medications.⁴ The histology sample showed images of double contours, podocyte hypertrophy and decrease in vascular lumen, characteristic of TMA and associated with the use of SUN.³

AKI associated with checkpoint inhibitors has also been described.^{5,6} It generally occurs three to six months after the first dose and patients have leucocyturia and non-nephrotic proteinuria.⁵ The characteristic histology finding is the presence of infiltrate in the interstitium.⁶ Cortazar et al. recently




Fig. 2 – Electron microscopy with enlargement of the lamina rara interna (arrows) which can be seen in thrombotic microangiopathy.

described a series of 12 patients with tubulointerstitial nephritis associated with the use of checkpoint inhibitors.⁶ Unlike the AIN induced by other drugs, in which the infiltrate is usually formed by eosinophils, in this case, the infiltrate is mainly of lymphocytes. This may be the result of a different mechanism, deriving from a reprogramming of the immune system leading to a loss of tolerance against endogenous antigens in the kidneys, which would also explain the latency period between administration and onset of the adverse effect.⁶

The treatment in both cases is discontinuation of the drug that is causing the kidney damage. In the case of the NIV-induced AIN, the use of corticosteroids has been shown to recover renal function in most situations.^{5,6}

One important question is whether a patient who has had kidney damage induced by these drugs should receive the medication again. Most series recommend complete discontinuation if toxicity reaches grade III-IV, or if haemodialysis is required.^{5,6} A balance needs to be made between the oncological benefits of continuing treatment and the risk of recurrence of the kidney disease. Therefore, we recommend close mon-

itoring of the patient, including monitoring of renal function and blood pressure, in order to be able to act quickly and avoid irreversible damage.

REFERENCES

1. Gurevich F, Perazella MA. Renal effects of anti-angiogenesis therapy: update for the internist. *Am J Med.* 2009;122:322–8.
2. Motzer RJ, Tannir NM, McDermott DE, Arén Frontera O, Melichar B, Coueiri TK, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. *N Engl J Med.* 2018;378:1277–90.
3. Eremina V, Jefferson JA, Kowalewska J, Hochster H, Haas M, Weisstuch J, et al. VEGF inhibition and renal thrombotic microangiopathy. *N Engl J Med.* 2008;358:1129–36.
4. Azar I, Esfandiari S, Sinai P, Wazir A, Foulke L, Mehdi S. Sunitinib-induced acute interstitial nephritis in a thrombocytopenic renal cell cancer patient. *Case Rep Oncol Med.* 2017;2017:6328204.
5. Wanchoo R, Karam S, Uppal NN, Barta VS, Deray G, Devoe C, et al. Adverse renal effects of immune checkpoint inhibitors: a narrative review. *Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors. Am J Nephrol.* 2017;45:160–9.
6. Cortazar FB, Marrone KA, Troxell ML, Ralto KM, Hoenig MP, Brahmer JR, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. *Kidney Int.* 2016;90:638–47.

Candela Moliz^{a,*}, Teresa Caveró^a, Enrique Morales^a, Eduardo Gutiérrez^a, Marina Alonso^b, Manuel Praga^a

^a Servicio de Nefrología, Hospital Universitario 12 de Octubre, Madrid, Spain

^b Servicio de Anatomía Patológica, Hospital Universitario 12 de Octubre, Madrid, Spain

* Corresponding author.

E-mail address: candelamoliz@gmail.com (C. Moliz).

11 February 2019

<https://doi.org/10.1016/j.nefro.2020.03.007>

2013-2514/© 2020 Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Nefrología. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).